A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists

Dolph, M., Roy, A., Bhor, M., Hearnden, J., Kwon, C. S., Forsythe, A., Tremblay, G. and Briggs, A. (2018) A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists. Journal of Comparative Effectiveness Research, 7(8), (doi:10.2217/cer-2018-0034) (PMID:29848048)

Dolph, M., Roy, A., Bhor, M., Hearnden, J., Kwon, C. S., Forsythe, A., Tremblay, G. and Briggs, A. (2018) A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists. Journal of Comparative Effectiveness Research, 7(8), (doi:10.2217/cer-2018-0034) (PMID:29848048)

Full text not currently available from Enlighten.

Abstract

Aim: Eltrombopag and romiplostim are comparable second-line therapies in chronic immune thrombocytopenia. Treatment decisions are made in different contexts. A framework was created to outline decision pathways for physicians and payers. Materials & methods: The costs of drugs, administration, routine care, bleeding, other adverse events and mortality were included in the year-long calculation of total costs from a US private payer perspective. Treatment parameters and outcome data were obtained from relevant clinical trials. Results: The total cost per year, per patient of eltrombopag was US$51,000 versus US$76,000 for romiplostim. Drug costs and costs associated with bleeding-related events were the main drivers of cost difference. Conclusion: This framework facilitates decision-making in the management of chronic immune thrombocytopenia with eltrombopag and romiplostim.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Briggs, Professor Andrew
Authors: Dolph, M., Roy, A., Bhor, M., Hearnden, J., Kwon, C. S., Forsythe, A., Tremblay, G., and Briggs, A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Health Economics and Health Technology Assessment
Journal Name:Journal of Comparative Effectiveness Research
Publisher:Future Medicine
ISSN:2042-6305
ISSN (Online):2042-6313
Published Online:31 May 2018

University Staff: Request a correction | Enlighten Editors: Update this record